experimental fate or toxicity data available. The presented computational analysis thus helps 23 setting priorities for further testing. 24 Separate treatment of hospital wastewater would reduce the pharmaceutical load of 25 wastewater treatment plants, and the risk from the newly identified priority pharmaceuticals. 26 However, because high-risk pharmaceuticals are excreted mainly with feces, urine source 27 separation is not a viable option for reducing the risk potential from hospital wastewater, while 28 a sorption step could be beneficial. exposure to estrogenic compounds (Routledge et al., 1998 , Kidd et al., 2007 . Likewise, the 19 adverse effect of diclofenac on vulture populations in Pakistan (Oaks et al., 2004) 20 demonstrates that under specific exposure conditions pharmaceuticals can cause problems. 21 Increasingly, also negative effects of pharmaceuticals that are not related to the 22 pharmacological effect (Owen et al., 2007) or its side effect (Oaks et al., 2004 ) are found 23 (Tarazona et al., 2010) , e.g. specific inhibition of photosynthesis in algae caused by ß-blockers 24 (Escher et al., 2006 ) and fluoxetine (Neuwoehner et al., 2009 ). Furthermore, in reality, rather 25 than single compounds we find complex mixtures of pharmaceuticals and metabolites that 26 may interact or show concentration additivity (e.g. Altenburger et al., 2004 , Brian et al., 27 2007 . Wastewater experts and policy makers are currently discussing whether 28 micropollutants give sufficient rise to concern to justify removal measures from wastewater To date the contribution of hospitals to the pharmaceutical load in wastewater is unclear, since 24 e.g. contraceptives or painkillers are widely used in the population. Various projects, including 25 a large EU-consortium called "PILLS" (www.pills-project.eu) are currently determining the 26 significance of hospitals as point sources for pharmaceuticals and pathogens, including multi-27 antibiotic resistant bacteria. In Switzerland, 18% of the total volume of the "most-sold top 100 28 active compounds list of pharmaceuticals" (IMS, 2004) is being administered in hospitals 29 (Weissbrodt et al., 2009) . In mass flow studies in a Swiss hospital, 50% of all X-ray contrast 30 media, but only a few percent of the investigated cytostatics were recovered in the hospital 31 sewer (Weissbrodt et al., 2009) . The low recovery is mainly explained by pharmaceuticals 32 consumed in the hospital but excreted at home by out-patients (50% out-patients for X-ray 33 contrast media and 70% for cytostatics in this example). Cytostatics are considered to be 1 especially harmful to the environment and are mainly administered in hospital settings (Lenz 2 et al., 2007) . 3 Ort et al. recently determined the fractions of pharmaceuticals stemming from hospitals using 4 a clever sampling design and chemical analytical quantification of 59 pharmaceuticals (Ort et 5 al., 2010) . For most pharmaceuticals the contribution of hospitals to overall wastewater was 6 lower than 15%, with exception of two antibiotics (contrast media were not included in this 7 study). These Australian results were consistent with a Norwegian analysis (Langford and 8 Thomas, 2009) . Similarly, the load of endocrine-disrupting chemicals did not differ between 9 hospital and general wastewater (Pauwels et al., 2008) . 10 11
The dose makes the poison 12
Mass fluxes alone are insufficient to evaluate the risk stemming from pharmaceuticals; their 13 ecotoxic potential needs to be considered, what to our knowledge has not been done for 14 hospital wastewater so far. The risk quotient (RQ) is defined as predicted environmental 15 concentration (PEC) divided by the predicted no effect concentration (PNEC), which is 16 extrapolated preferentially from chronic toxicity data, or, if no chronic data are available, from 17 acute toxicity data (EMEA, 2006, European Parliament and European Council, 2006a). 18
Despite recent large efforts to increase the database on ecotoxicological effects of 19 pharmaceuticals (PhACT Database, 2006) , there remain significant data gaps, especially when 20 it comes to chronic effect data (Crane et al., 2006) . Data gaps can be closed with predictive 21 models using Quantitative Structure Activity Relationships (QSAR) but again chronic QSARs 22 are less readily available (European Chemicals Agency, 2008, Escher et al., 2009). Therefore, 23 the following analysis is based on acute toxicity data and uses an assessment factor of 1000 to 24 extrapolate the PNEC, which is 100 times higher than the assessment factor of 10 25 recommended in the EMEA guideline to be used in association with chronic toxicity data. 26 This implicitly accounts for an acute-to-chronic ratio of 100, which should be protective for 27 most modes of toxic action, apart from endocrine effects as is discussed in section 3.3. 28 Previous attempts to predict the risk of large lists of pharmaceuticals (Sanderson et al., 2004) 29 were of limited use because they did not account for the speciation of pharmaceuticals. 30
However, over 60% of pharmaceuticals are acids or bases that are fully or partially dissociated 31 at ambient pH (Avdeef, 2003) . Therefore, classical QSAR models cannot be applied without 32 adaption and consideration of speciation of pharmaceuticals (Tarazona et al., 2010) . 33 6 Additionally to the risk from individual pharmaceuticals, also the risk from different mixtures 1 should be estimated. We recently developed a toxicity model for mixtures consisting of an 2 individual pharmaceutical and its metabolic transformation products (Escher et al., 2006 , 3 Lienert et al., 2007b . It can also be applied to mixtures of groups of different pharmaceuticals 4 with a common (therapeutic) mode of action using the assumption of concentration addition of 5 mixture toxicity -or for concentration addition of the underlying baseline toxicity for all 6 groups of pharmaceuticals as discussed below. 7 8
Mixture toxicity of pharmaceuticals 9
Pharmaceuticals are designed to be bioactive (with exception of contrast agents, which are 10 rather diagnostics than pharmaceuticals). In non-target aquatic life many act as baseline 11 toxicants. However, some exhibit the therapeutic effect also in aquatic life as the unwanted 12 estrogenic effects on fish (Kidd et al., 2007) . Others act via a different specific mode of toxic 13 action, as evidenced for fluoxetine effects on algae (Neuwoehner et al., 2009) . It is generally 14 accepted that mixtures with components exhibiting the same mode of action act according to 15 the model of concentration addition. If all components act according to a strictly different 16 mode of action they cannot be modeled with concentration addition but act according to the 17 All chemicals, regardless of whether they have a specific mode of toxic action, also exert a 31 baseline toxic effect (van Wezel and Opperhuizen, 1995). There is typically a threshold 32 concentration below which the specific mode of toxic action is not observed and above which 33 7 it is. At the concentrations at which acute toxicity usually occurs, the toxicity of a single 1 pharmaceutical will be predominantly due to the specific mode of toxic action. However, in  2   mixtures the concentration of each single component decreases, while the number of  3 components with various different specific modes of toxic action increases. Therefore, the 4 contribution to the total toxicity by the specific mode of toxic action decreases while that for 5 the non-specific baseline toxicity increases (ECETOC, 2001). Warne and Hawker used this 6 concept to develop the Funnel Hypothesis (Warne and Hawker, 1995) . The Funnel Hypothesis 7 argues that the more components an equitoxic mixture (a mixture where each chemical 8 contributes the same to toxicity) contains, the larger the likelihood is that the compounds with 9 specific modes of toxic action will not dominate the mixture toxicity. Thus the components 10 will increasingly act only by their baseline mechanism of action and should be concentration 11
additive. 12
In wastewater, we have a large number of components of varying modes of toxic action. Thus 13 we can assume that the toxicity of a very complex mixture is governed by the underlying 14 baseline toxicity, not the specific mode of toxic action of single components. For risk 15 assessment, if concentration addition can be assumed, the risk quotients of the individual 16 pharmaceuticals can be added up to yield a sum risk quotient (RQ mix ). 17 18
Ecotoxicological risk potential in four scenarios 19
The aim of this study was to estimate the risk potential of wastewater containing 20 pharmaceutical mixtures from two point sources. The 100 active ingredients excreted in the 21 highest amounts in 2007 from two different hospitals, one general hospital and one psychiatric 22 center were compared. 23
To evaluate the elimination of pharmaceuticals in conventional wastewater treatment plants 24
(WWTP) and the effect of dilution of the hospitals' wastewater in the sewer, we compared the 25 following four scenarios for both hospitals: 26 Scenario 1 HWW: Risk potential of the wastewater of the hospital main wing, before 27 discharge to the sewer (i.e. full risk potential without any degradation or dilution). 28 Scenario 2 WWTP influent: Risk potential at inlet of the WWTP (i.e. reduction of 29 risk potential through dilution in sewers). 30
Scenario 3 WWTP effluent:
Risk potential at discharge of the WWTP (i.e. reduction 31 of risk potential through degradation and sorption process during conventional 32 biological treatment; including dilution in sewers). 33 8 Scenario 4 HWWTP effluent: Risk potential at the hospital main wing after 1 hypothetical conventional biological treatment (i.e. reduction of risk potential through 2 degradation and sorption process in conventional biological treatment without 3 dilution). This scenario thus assumes that some sort of biological treatment would be 4 installed in the main wing of the hospital to deal with the wastewater; in an ideal case, 5 the wastewater might then be directly discharged to surface waters or infiltrated). 6 7 2. MATERIALS AND METHODS 8
General hospital 9
The first case is a typical, regionally important general hospital in Switzerland with 338 used 10 beds serving more than 250000 inhabitants. In 2007, there were 122814 "days of care" and 11 16013 patients leaving the hospital. The whole range of medical services is offered, e.g. 12 internal medicine, oncology, surgery, maternity clinic, nuclear medicine, and radiology, 13
including computer tomography (CT) and magnetic resonance imaging (MRI). In 2008, 11767 14
CTs were carried out, of which 7490 were with X-ray contrast media; and 5154 MRIs (2691 15 with X-ray contrast media). Around two thirds of these X-rays were carried out with out-16
patients. 17
In 2008, 209251 m 3 water was used in total, and 115690 m 3 in the main hospital wing that 18 hosts patients and where pharmaceuticals are excreted. Wastewater is discharged to a WWTP 19 with conventional biological treatment, which serves 54133 inhabitants. In 2007, the WWTP 20 treated 8641486 m 3 wastewater, and discharged 564993 m 3 without treatment in combined 21 sewer overflows during rain events. Pharmaceutical concentrations in the hospital wastewater 22
were calculated for the main hospital wing. For the dilution to the WWTP influent, the 23 combined sewer overflow was not considered, resulting in a dilution factor df of 0.013, 24
The hospital kindly provided data of the pharmaceuticals administered in 2007. We The amount of active ingredient in the pharmaceuticals was evaluated from Swiss drug 28 documentations (Documed, 2009) and the sum of each ingredient calculated. Amounts of 29 active compounds excreted unchanged in urine and feces were calculated using excretion rates 30 from literature (Lienert et al., 2007a , Documed, 2009 ). If excretion was not clearly given, 31 worst case scenarios with highest suggested excretion were taken. For active ingredients been 32 9 used as cremes, an excretion of 75-100% was assumed, since wash off from the skin is also a 1 source of water contamination without undergoing metabolism in human body. We assumed 2 that all pharmaceuticals were excreted in the hospital, i.e. we neglected pharmaceuticals 3 thrown away, and excretion by out-patients. The 100 active ingredients excreted in the highest 4 amounts (Top-100 pharmaceuticals) were analyzed further in this study . 5 In 2007, 1154 kg of pharmaceuticals were consumed in the hospital, of which 779 kg were 6 excreted. The Top-100 list accounts for 1137 kg consumed pharmaceuticals (777 kg excreted). 7
"Natural" ingredients such as metals, carbohydrates, sugars, enzymes, paraffin oil, herbal 8 medicines etc. were omitted from the analysis. However, we included synthetic laxatives and 9 synthetic sugars. 
Psychiatric center 19
The psychiatric case study is a regionally important Swiss psychiatric center with 211 used 20 beds, providing stationary and ambulatory services. In 2007, 2008 patients received stationary 21 treatment, with 76855 "days of care". Besides acute adult psychiatry, there are e.g. wards for 22 psychotherapy, addictive disorders, and geriatric psychiatry. There is also a housing group and 23 working place for long-term psychiatric patients. According to interviews with head 24 physicians and nurses (Lienert and Mosler, in prep.), many patients have acute psychiatric 25 disorders. These are often in an extreme state at admission requiring strong medication. 26
Therefore, there is a focus on pharmaceutical treatment . 27 In 2007, 23250 m 3 water was used in the psychiatric hospital. It is discharged to a WWTP, 28 which treats 1742000 m 3 raw wastewater with conventional biological treatment and serves 29 14603 inhabitants, yielding a dilution factor of the wastewater df of 0.013. 30
In 2007, 52 kg of pharmaceuticals were consumed in the psychiatric hospital, of which 17 kg 31 were excreted. As above, these numbers were calculated from the amounts of pharmaceuticals 32 administered, which were kindly provided by the hospital. The Top-100 list, which consists of 33 the 100 active ingredients excreted in the highest amounts, accounts for 50 kg of consumed 1 pharmaceuticals, of which 17 kg were excreted. Again, "natural" ingredients such as metals, 2 carbohydrates, sugars, enzymes, paraffin oil, herbal medicines etc. were discarded, but 3 synthetic laxatives, such as synthetic sugars, included. These 17 kg excreted in the psychiatric 4 center represent approximately 5% of the pharmaceuticals reaching the WWTP (359 kg per 5
year in total) assuming a general excretion of 23.4 g per year per Swiss inhabitant as explained 6 above. 7 8
Exposure Assessment 9
In the following, the calculation of the predicted environmental concentration PEC for the four 10 scenarios is described. Only parent compounds were regarded and concentrations were 11 corrected for metabolism in the human body. Metabolites were neglected because previous 12 analysis showed that the contribution of metabolites to the overall risk is typically not very 13 high. Moreover, exposure to metabolites is very difficult to assess due to highly variable 14 literature reports on excreted metabolite fractions (Lienert et al., 2007b) . preparations. We derived m i from the units consumed for each drug preparation, U i , and the 23 amount of active ingredient contained in each unit, m Ui (g). 24
In scenario 2, PEC WWTPinfluent was defined to be equivalent to the PEC HWW multiplied with the 26 dilution factor df in the sewer and corresponds to the concentration of pharmaceuticals at the 27 inlet of the WWTP. The df was 0.013 for both, the the general hospital and the the psychiatric 28 center. 29  PEC WWTPinfluent  df  PEC HWW (3) 30 11 In scenario 3, PEC WWTPeffluent refers to the discharge of the WWTP, where the PEC WWTPinfluent 1 was reduced by conventional biological secondary treatment with sludge age > 3 days in 2 municipal wastewater treatment, including removal of organic material and 3 denitrification/nitrification. Data on biodegradation were compiled from the literature 4 (Supporting Information, Tables SI-1 and SI-2). The fraction eliminated in the treatment plant 5 f elimination in WWTP was assumed to be 0% if no literature data were available. 6
For scenario 4, the same elimination rates were assumed for the wastewater treatment directly 8 in the hospital (without dilution in the sewer), which yields the PEC HWWTPeffluent . 9 4. Search for data with google scholar (http://scholar.google.com.au/) using search terms 23 "compound name", "EC50", and "algae"/"daphnia"/"fish". 24
Whenever possible, toxicity data that are consistent with the species of the selected QSAR 25 were chosen to calculate baseline toxicity (see below). If such data were not available, the 26 lowest acute EC/LC50 of another closely related biological species was chosen. If no acute 27 value was available, also chronic toxicity data were used. However, as the discussion below 28 demonstrates, ecotoxicological literature data on pharmaceuticals remains scarce and there is 29 not enough chronic toxicity data available to base the analysis upon. Therefore toxicity was 30 estimated with QSARs exclusively to avoid inconsistencies between data-rich and data-poor 31 compounds. 32 1
QSAR model to predict baseline toxicity 2
To calculate baseline toxicity of the 100 quantitatively most important compounds in each 3 case study, established QSARs for algae-, daphnia-, and fish toxicity were used. The QSARs 4 were selected from the Technical Guidance Document of the EU (European Commission, 5 2003) because they constitute a well-validated and often applied set. 6
Most published baseline QSAR models were set up for neutral organic molecules and use the 7 octanol-water partition coefficient K ow as hydrophobicity descriptor. However, many 8 pharmaceuticals are acids or bases (Tarazona et al., 2010) . For these, K ow is an unsuitable 9 measure of bioaccumulation and surrogate for biomembranes, the target site for baseline 10 toxicants. In pharmaceutical science, the liposome water distribution coefficient at a defined 11 pH value, e.g. pH 7, D lipw (pH 7) has replaced the K ow as a descriptor for uptake into biological 12 membranes. More recently, this model was also adapted in environmental science. For a 13 historic overview refer to (Escher and Sigg, 2004). The logarithm of D lipw (pH 7) was therefore 14 used in the QSARs for baseline toxicity (Table 1) to calculate the toxicity of the compound 15 towards the three aquatic organisms, algae, daphnia, and fish. 16 To calculate D lipw (pH7) from the K ow , following steps were undertaken for each compound: http://www.syrres.com) were checked for an experimentally derived octanol-water 32 13 distribution coefficient K ow . If no experimental value was found, the value estimated 1 by a program of U.S. EPA (Kowwin v. 1.67, U.S.EPA, 2008) was used. As 2 comparison, the K ow was also calculated using the online prediction program SPARC 3 (Hilal et al., 2005) . Contrary to Kowwin, which is based on a database of compounds 4 with known K ow , SPARC calculates K ow values ab-initio from quantum mechanics. 5 B. Selecting K ow and sorting out compounds without baseline toxicity: If the 6 experimental or estimated value by Kowwin was logK ow > 0 and less than 10 times 7 greater or smaller than the value estimated by SPARC (logK ow ± 1), the former was 8 used for all further calculations. If both logK ow (experimental/Kowwin and SPARC) 9
were negative (i.e. logK ow < 0, no accumulation in an organism), the compound was 10 considered to show no baseline toxicity due to its low tendency to partition into 11 biomembranes and insignificant contribution to the mixture toxicity. These compounds 12
were excluded from all further calculations. If the two K ow differed more than an order 13 of magnitude, several more estimation programs were used and the K ow from either 14 
We have discussed the limitations of using ∆mw of 1 on numerous occasions (Escher and 31 Sigg, 2004, Neuwoehner et al., 2009 ). Since the database is too limited to generate more 32 14 precise estimates for ∆mw, we kept the generic value of 1. Zwitterionic compounds were 1 treated with a ∆mw of 1, too, despite their overall net neutral charge because often the 2 opposite charges are spatially isolated. 3 4
Calculating the predicted no-effect concentration (PNEC) 5
To estimate the predicted no-effect concentration (PNEC), the lowest QSAR-based EC50 6 value (i.e. for the most sensitive species; either fish, daphnia, or algae) of each compound was 7 divided by 1000. The Technical Guidance Document of the European Commission (2003) 8 suggests an assessment factor of 1000 if acute toxicity data (for example EC50 i , effect 9 concentration of pharmaceutical i) are available in at least three test systems on three trophic 10 levels: algae, daphnia, fish. 11  PNEC i  EC50 i 1000 (9) 12 13 2.5. Risk analysis 14
Calculating the risk quotient (RQ) of single compounds 15
For each pharmaceutical i, the risk quotient RQ was calculated as an indicator for 16 ecotoxicological risk. The RQ is the ratio between the predicted concentration in the 17 environment PEC and the concentration at which no effect is expected PNEC (EMEA 2006 calculations for mixtures must be based on a common species. Therefore, we assessed the risk 23 for algae, daphnia, and fish individually and then selected the species with the highest 24 resulting RQ mix for further analysis. We also point out that for hospital wastewater, cytostatic 25 and antibiotic effects are of particular concern. However, there are only limited and non-26 standard ecotoxicological data available for these mechanisms. The sum of the risk quotients of the Top-100 pharmaceuticals in each hospital was computed 1 to allow comparing drug cocktails of variable compositions. According to the concept of 2 concentration addition, the combined effect of the components is equal to the sum of the 3 concentrations of each chemical expressed as a fraction of its own individual toxicity (Brown, 4 1968 , Sprague, 1970 . Concentration addition holds if the components of a mixture exhibit the 5 same mode of toxic action. Since toxicity was estimated using a baseline toxicity QSAR for 6 all compounds, this condition is fulfilled for the QSAR estimates but not necessarily for the 7 experimental toxicity. If individual pharmaceuticals exhibit a specific mode of toxic action 8 (which would be underestimated by the baseline toxicity QSAR), this specific effect would 9 contribute to the mixture toxicity according to independent action, which is a generally lower 10 contribution than one from concentration addition. Thus it is likely that the underestimation of 11 specific toxicity is cancelled out because the contribution of this component is given a higher 12 weight by using the mixture toxicity model with concentration addition instead of the model 13 with independent action for specific toxicity. By comparing RQ i of single compounds to the total risk of the mixture RQ mix , the 19 pharmaceuticals or groups of pharmaceuticals of greatest concern can be identified and further 20 assessed. 21 22 23
RESULTS AND DISCUSSION 24

Mass fluxes in hospital wastewater 25
The general and psychiatric hospitals showed very different pharmaceutical usage patterns in 26
2007 (Tables 2 and 3 ). First, the total amount of pharmaceuticals differed substantially. In the 27 general hospital, 779 kg were excreted, from which we can predict a load excreted from each 28 "bed" of 2.3 kg per year. In the psychiatric hospital only 17 kg were excreted, which gives an 29 excreted load of 0.08 kg per bed. Second, also the types of pharmaceuticals differed 30 16 significantly. In the general hospital, 58% of the excreted load stemmed from X-ray contrast 1 media, 19% from laxatives, 16% from antibiotics, and 8% from others. In the psychiatric 2 hospital, the main fraction came from laxatives with 36%, followed by 3 analgesics/antiphlogistics to 17%, antidiabetics to 15%, psychotropic pharmaceuticals to 11%, 4 and others to 21%. 5
Even though all these pharmaceuticals were administered in the hospital, it is unclear, which 6 fraction was excreted in the hospital and which fraction was taken home by out-patients. A 7 mass flow study in another hospital showed that only 50% of all X-ray contrast media were 8 excreted there (Weissbrodt et al., 2009 ). In our case study hospital, two thirds of the patients 9 typically go home after receiving an X-ray, thus a significant fraction of pharmaceuticals will 10 also be excreted at home. Likewise, since many older patients are in hospital, they take a 11 number of pharmaceuticals regularly that they bring into the hospital. Since it is impossible to 12 make an exact mass balance of which pharmaceuticals are excreted where, we assumed the 13 worst case that all pharmaceuticals administered in the hospital would also be excreted there. 14 Likewise, we did not account for the pharmaceuticals brought in by patients. 
High consumption does not always translate to high risk 20
The ten highest ranked PEC HWW , i.e. the concentration of different active ingredients in the 21 hospital wastewater, constituted 5970 µg/L in the general hospital. This equaled 89% of the 22 sum of all Top-100 PEC HWW ( Table 2 and Table SI -1 in the Supporting Information). 23
However, the mixture toxicity RQ mix , i.e. the sum of the risk quotients of these Top-10 24 pharmaceuticals amounted only to 1.0, equaling 0.4% of the RQ mix of the Top-100 25 pharmaceuticals. The reason is that among the Top-10 pharmaceuticals only two (4-26 methylaminoantipyrine and amoxillin) showed significant ecotoxicity (logD lipw (pH 7) > 0; 27 A similar result on the exposure side was obtained for the psychiatric hospital, where the Top-31 10 PEC HWW summed up to 603 µg/L, which is 81% of the sum of all Top-100 PEC HWW (Table  32 3 and Table SI-2 in the Supporting Information). However, the effect analysis came to a 33 different conclusion than for the general hospital. There were only four pharmaceuticals in the 1 Top-10 list that were not ecotoxic (logD lipw (pH 7) < 0; Table SI-4), namely the laxative 2 macrogol, the antidiabetic metformin, magaldrate, a drug for acid related disorder, and the 3 antiepileptic gabapentin. All others showed substantial ecotoxicity potential (diclofenac, 4 ibuprofen, venlafaxine, amoxicillin, amisulpride, paracetamol). Consequently, the Top-10 5 pharmaceuticals with respect to their exposure amounted to 23% of RQ mix (Table 3) . 6 Figures 1A and 1B compare the PEC HWW with the risk quotients of the different scenarios 7 investigated. The data are ranked with decreasing PEC HWW and all data are included, while 8 Tables 2 and 3 only include the results with RQ HWW < 0.01). Obviously, there is no correlation 9 between PEC and RQ (Pearson's R < 0.1). There were only few pharmaceuticals with a RQ > 10 1 in the hospital wastewater and these mostly had a PEC HWW < 10 µg/L. A notable exception 11 is diclofenac, whose risk was equally driven by exposure and effect. 12
For most other compounds the main driver determining the RQ was the PNEC (Figure 2 ). This 13 observation is substantiated by the fact that the PEC HWW varied in our selected dataset by less 14 than four (general hospital, Table 2 ) and three (psychiatric center, Table 3 ) orders of 15 magnitude, while the PNEC values covered almost eight orders of magnitude, resulting in an 16 overall range of the RQ of more than seven orders of magnitude ( Figure 2 ). 17
This analysis is relevant to prioritize pharmaceuticals for risk assessment. Generally, those 18 pharmaceuticals with a high consumption are selected for further investigation and risk 19 assessment, which is reflected by many studies on these compounds. However, those 20 pharmaceuticals are not necessarily the most relevant ones with respect to their environmental 21 risk as our present analysis indicates. 22 2007). Due to its instability no toxicity data exist for progesterone and it is justified to neglect 8 the specific progestagen activity in the risk analysis. 9
As fish have corticosteroid receptors (Prunet et al. 2006 ), this might translate into a specific 10 effect, but there are no experimental data available for corticosteroids apart from an ACR of 11 10 for algae (Crane et al. 2006) . 12
In addition, it cannot be fully excluded that none of the other pharmaceuticals exhibits a 13 different and more sensitive mode of toxic action in a chronic toxicity study. This would cause 14 an underestimation of the RQ of the individual components, and if these particular 15 components had a large contribution to the mixture toxicity, the assumptions regarding the 16 mixture toxicity model could be flawed. Nevertheless, based on currently available data, we 17 regard our screening approach as a valuable contribution to risk assessment of hospital 18
pharmaceuticals. 19
Even experimental acute toxicity data were only available for a very limited set of compounds 20 (Tables SI-5 and SI-6 in the Supporting Information). 16/15 (general/psychiatric hospital) 21
acute EC50 values were found for algae (Tables SI-5A and SI-6A), 19/21 acute EC50 for 22
Daphnia (Tables SI-5B and SI-6B), and 16/18 acute LC50 for fish (Tables SI-5C and SI-6C). 23
Thus even if one resigns to acute toxicity data, less than 20% of the pharmaceuticals under 24 investigation actually have experimental toxicity data. This percentage would not be sufficient 25
for the envisaged analysis. Therefore, we had to use the QSAR models for the prediction of 26
toxicity. 27
To evaluate if the experimental toxicity data point to a specific mode of toxic action or if it 28 can be explained by baseline toxicity, we performed a toxic ratio analysis. This analysis helps 29 to decide if the use of baseline toxicity QSARs is justified or if there is a high probability that 30 QSAR predictions lead to underestimation of toxicity as the pharmaceutical analyzed exhibits 31 a specific mode of toxic action to the organism under evaluation. 32 19 The toxic ratio TR (eqn 14) is a measure of the specificity of effect (Maeder et al. 2004 ). If TR 1 > 10, i.e., the experimental toxicity is at least ten times higher than the one predicted from the 2 baseline toxicity QSAR, then the compound is likely to have a specific mode of action 3 (Verhaar et al. 1992 ). If TR ≤ 10, the given compound exhibits merely baseline toxicity. 4  TR  EC 50,baselinetoxicity EC 50,exp erimental (14) 5
The majority of pharmaceuticals with experimental toxicity data could be classified as 6 baseline toxicants with a toxic ratio analysis. Of the 15/16 experimental algae toxicity data, 7 only three antibiotics had a TR exceeding 10 (Tables SI-5 and SI-6). Clarythromycin had a TR 8 of 61165, sulfamethoxazole of 2867, and erythromycin of 6585. Metoprolol had a TR of 71, 9
but another algal species was tested than Pseudokirchneriella subcapitata, which we use for 10 QSAR calculations. For trimethoprim, a TR of 24 was derived from a NOEC value, so no 11 quantitative comparison should be made due to mismatch of endpoints. Out of the 19 12 experimental Daphnia magna data, two analgesics, tramadol (TR = 814) and paracetamol (TR 13 = 59) indicated specific toxicity. The TR of sulfamethoxazole of 16 was slightly increased but 14 it is uncertain whether it exhibits a specific mode of toxic action as in algae. In fish, only one 15 out of 16/18 experimental data points yielded a TR >10 but this value for tramadol is not 16 reliable, since the fish species tested was not indicated. 17
If we extrapolate the results of the TR analysis of this fraction of pharmaceuticals for which 18 experimental data were available to all pharmaceuticals evaluated in this study, we can safely 19 assume that > 90% of the top-100 pharmaceuticals act as baseline toxicants to the non-target 20 aquatic organisms and that the remainder (< 10%) will not dominate the toxicity of the 21 mixture (see section 1.5). We conclude that the QSAR model for baseline toxicity is valid to 22 predict the toxicity of our mixtures of hospital wastewater. For 54 (general hospital) and 72 23 (psychiatric hospital) of the Top-100 pharmaceuticals, it was possible to derive a toxicity 24 estimate. For the remainder, the predicted lipophilicity was so small (logD lipw (pH 7) < 0) that 25 independent of the PEC no contribution to the toxicity was expected. 26 27
On which biological species to base risk evaluation? 28
In principle, PNEC must be derived from the biological species with the lowest EC 50 by 29 extrapolation with an uncertainty factor of 1000 (TGD, European Commission, 2003). This 30
can be a different biological species for each pharmaceutical. However, for the mixture risk 31 quotient, we have to work with a single species and cannot sum up risk quotients from 32 20 different species. To choose the species for the final risk evaluation, PNECs were defined for 1 each species separately, and risk quotients for all single pharmaceuticals calculated and 2 summed up for each species. In the general hospital, RQ mix was 239 for algae, 145 for 3 Daphnia, and 48 for fish. In the psychiatric hospital, RQ mix was 114 for algae, 77 for Daphnia, 4 and 31 for fish. Hence, for both hospitals, algae produced the highest RQ mix and fish the 5 lowest, with a factor of five between the highest and the lowest RQ mix for the general hospital 6 and a factor of 4 for the psychiatric hospital. Thus in all further evaluations, the effect data for 7 algae were used. The PNEC values reported in Tables 2 and 3 are those for green algae but the 8 results for all biological species are given in the Supporting Information (Tables SI-5 and SI-9 6). 10 11
Mixture risk quotients in undiluted hospital wastewater 12
The risk from the mixture of pharmaceuticals RQ mix for scenario 1, i.e., hospital wastewater of 13 the main wing without any dilution in the sewer, was 239 for the general hospital and 114 for 14 the psychiatric hospital (Tables 2 and 3 ). In the general hospital for 10, 18 and 31 15 pharmaceuticals, the RQ HWW was above 1, 0.1 and 0.01, respectively ( Figure 3A and Table 2),  16 while for the psychiatric center, 9, 26 and 42 pharmaceuticals exceeded an RQ HWW of 1, 0.1 17 and 0.01, respectively ( Figure 3B and Table 3 ). 31 pharmaceuticals in the general hospital and 18 42 pharmaceuticals in the psychiatric center made up more than 99 % of the RQ mix (i.e. had a 19 RQ > 0.01) but together they constituted only 14% (general hospital) and 30% (psychiatric 20 center) of the PEC HWW . All of those with RQ HWW > 0.01 are depicted in Figure 3 and are 21 further discussed below. 22 23
Unexpected "high-risk" pharmaceuticals 24
Amiodarone, which had the highest ranked risk quotient RQ HWW of 86 in the wastewater of 25 the general hospital (Table 2) is an antiarrhythmic agent with numerous severe side effects. It 26 is used in hospitals for cardiac arrest, serious disrhythmias, and other life-threatening 27 situations (see http://www.drugs.com/amiodarone.html, accessed on 30 Nov 2009). It has been 28 demonstrated that amiodarone disrupts the bacterial cell membrane and decreases bacterial 29 growth (Rosa et al., 2000) . Amiodarone, whose reported human side effect is cytotoxicity on 30 thyroid follicular cells, also decreased T4 levels in zebra fish larvae (Raldua and Babin, 2009). 31
No classical experimental ecotoxicity data were available for this pharmaceutical. However, 32 the high experimental logK ow of 7.8 (Table SI- 3) yields a high toxicity prediction despite the 33 21 fact that the tertiary amine amiodarone is almost completed protonated and thus positively 1 charged at pH 7. 2 Ritonavir dominated the RQ mix of the psychiatric hospital with a RQ HWW of 31 (Table 3)  3 despite being only ranked 50 th with respect to exposure (Table SI- 2) . In the general hospital, 4 ritonavir was 3 rd (RQ HWW = 53, Table 2 ) and 60 th (PEC HWW ; and ecotoxicity had to be estimated due to lack of experimental data. The high logK ow of 6.27 9 (Table SI-3 and SI-4) together with its neutral speciation at pH 7 yields an exceptionally low 10 PNEC of 28 ng/L and consequently a high risk quotient (Table 3) counter antifungal agent. It is very hydrophobic with an experimental logK ow of 6.26 (Table  20 SI-3). As imidazole derivative it has a basic function but the acidity constant pK a is low 21 enough that at pH 7, the molecule is predominantly neutral. Both physicochemical properties 22 point to very high ecotoxicity, although few experimental data are available. Porsbring et al., 23 (2009) Not unexpectedly, diclofenac ranked third in the psychiatric hospital with a RQ HWW of 22 30 (Table 3 ) and also third with respect to exposure (PEC HWW = 73 µg/L, Table SI -2). This 31 reflects that its risk is equally driven by exposure and effect. However, in the general hospital 32 diclofenac ranked much lower (RQ HWW = 0.71, Table 2 ; exposure: 45 th rank, PEC HWW = 2.35 33 22 µg/L, Four of these overlapping pharmaceuticals, namely clopidrogrel, clotrimazole, meclozine, and 12 ritonavir were in the lower field of exposure ranking (ranked 50 th and higher) but exhibit a 13 high ecotoxicity potential. Ritonavir and clotrimazole stick out with their high log K ow and 14 have risk quotient RQ HWW > 1 in both hospitals as described in section 3.6. Meclozine and 15 clopidogrel exhibit RQ HWW > 1 in the general hospital. The other common four 16 pharmaceuticals, amoxicillin, oxazepam, tramadol, and pravastatin, have 0.01 < RQ HWW < 1. 17 18
Effect of biological treatment on risk quotient 19
The data on elimination of pharmaceuticals during wastewater treatment were collected from 20 various literature sources (Ternes, 2000 , Golet et al., 2003 , Loffler and Ternes, 2003 In Figure 3 , the risk quotients are plotted for all scenarios including those with elimination 29 during wastewater treatment and dilution in the sewer for all pharmaceuticals with RQ HWW 30 >0.01 and are ranked according to RQ HWW . This analysis is somewhat biased as for 55 of the 31
Top-100 pharmaceuticals in the general hospital and for 66 of the Top-100 pharmaceuticals in 32 23 the psychiatric center no literature data for biological elimination in wastewater treatment 1 were available and therefore no elimination was assumed (Tables SI-1 and SI-2). As is evident 2 from Figure 3 , dilution in the sewer generally had a larger effect on the decrease of the risk 3 quotient than the actual elimination for most pharmaceuticals. 4
For the pharmaceuticals with RQ HWW >1, dilution in the sewer decreased the RQ to around or 5 below 1 (RQ WWTPinfluent ≤ 1). The RQ WWTPeffluent decreased even further for clotrimazole and 6 ritonavir, the Top-2 and Top-3 risk pharmaceuticals for the general hospital, due to high 7 elimination rates in the WWTP. Ibuprofen was the only pharmaceutical in the group of 8 RQ HWW > 1 whose risk was reduced due to biological wastewater treatment, yielding a 9 RQ HWWTPeffluent < 1. However, for many pharmaceuticals in this group no elimination rates are 10 available. 11
Dilution in the sewer was more effective than removal by biological treatment. This is also 12 evidenced in the psychiatric center when the fourth highest ranked risk pharmaceuticals 13 (ritonavir, clotrimazole, diclofenac, mefenamic acid) all fell below RQ 1 due to dilution, while 14 biological treatment was beneficial but could not fully compensate for the high ecotoxicity 15 potential ( Figure 3B ). 16
A shortcoming of this analysis is that sorption to sewage sludge was not differentiated from 17 actual degradation. Hydrophobic chemicals sorb better to sewage sludge than hydrophilic 18 chemicals. The pharmaceuticals that dominate the RQ mix are all very hydrophobic and can 19 therefore be expected to be eliminated through sorption to sewage sludge. Clotrimazole and 20
Ritonavir are eliminated to > 80% during wastewater treatment ( 
Effect of urine source separation 25
The potential effect of urine source separation was also evaluated. Urine source separation is 26 considered beneficial because it reduces the nutrient and micropollutant load of wastewater 27 (Larsen et al., 2009, Lienert and Larsen, 2010) . The overall pharmaceutical load is mainly 28 expected in the fraction excreted with urine (e.g. Lienert et al., 2007 a, b) . Indeed, our survey 29 confirmed that the pharmaceutical load entering wastewater via feces was much lower than 30 that stemming from urine (Table 4 ). Exceptions were the laxatives, which are not taken up into 31 the circulation. Additionally, the more hydrophobic compounds tend to be rather eliminated 32 24 through feces than urine. In sum, 74% and 47% of the PEC HWW was coming from urine for the 1 general and psychiatric hospital, respectively (Table 4) indicate that urine and feces carry a share of the RQ. Despite the higher load of 8 pharmaceuticals in urine in the general hospital, the RQ HWW of the top-risk chemicals was 9 generally dominated by the fraction excreted with feces, while for the low-risk 10 pharmaceuticals urine was also a dominant excretory route (Tables SI-1 and SI-2 and dotted 11 line in Figure 4 ). The Top-3 pharmaceuticals, amiodarone/diclofenac, clotrimazole, and 12 ritonavir constitute 85% and 71% of RQ mix for the general and psychiatric hospital, 13 respectively, and all are excreted predominantly via feces. For ritonavir, urine also plays a 14 minor role, while for the two others urine is negligible as excretory route. As Figure 4 This analysis clearly demonstrates that urine source separation is a good mean to reduce the 21 overall load of micropollutants, but it does not reduce the high-risk compounds and the risk 22 potential of hospital wastewater. The high-risk compounds are all very hydrophobic, which 23 makes them intrinsically toxic but also causes excretion via feces because hydrophobicity and 24 water (urine) solubility are inversely correlated (Schwarzenbach et al., 2003) . Thus, a sorption 25 step as pretreatment of hospital wastewater would potentially be appropriate before release of 26 hospital wastewater into the communal sewer. 27 28 29
CONCLUSIONS 30
Despite limitations of the toxicity estimation model, the results of the present study give a 31 comprehensive picture on the risk posed by hospital wastewater. It allows setting priorities for 32 25 further experimental testing. Interestingly (but disturbingly), the pharmaceuticals likely to 1 pose the highest environmental risk have rarely been investigated previously. No or very few 2 experimental data are available for the physicochemical properties and/or ecotoxicity of 3 amiodarone, ritonavir, and clotrimazole, the three top-risk compounds in the general hospital. 4
In the psychiatric center, diclofenac was among the three top-risk compounds, together with 5 ritonavir and clotrimazole. Diclofenac is the only one of these pharmaceuticals that is well 6 researched in ecotoxicology and risk assessment. 7
As this analysis has demonstrated, the PNEC is generally the more important driver for the 8 RQ. The reason is that the variability in the PNEC among all pharmaceuticals investigated is 9 more than seven orders of magnitude while the PEC values cover only three to four orders of 10 magnitude among the group of 100 most used pharmaceuticals. This means that if 11 pharmaceuticals are selected only according to their usage pattern and occurrence, one might 12 miss relevant ones that could pose an environmental risk. Therefore, consumption data are less 13 suited to guide prioritization, but often the only available source for compound identification. 14 Thus hazard identification should precede risk assessment to prioritize according to intrinsic 15 hazard properties such as potential for persistence, bioaccumulation, and toxicity (PBT). The 16 regulation for industrial chemicals in Europe, REACH, has exactly taken this step by using a 17 PBT assessment to identify chemicals to be prioritized for further testing and risk assessment 18 
Baseline toxicity QSAR
Biological species
Scientific Name Toxicity endpoint Rescaled QSAR
Green algae
Pseudokirchneriella subcapitata 72-96h EC50 log(1/EC50(M)) = 0.95 . logD lipw (pH 7)+ 1.53
Water flea Daphnia magna 48h EC50 log(1/EC50(M)) = 0.90 . logD lipw (pH 7)+ 1.61
Fish Pimephales promelas 96h LC50 log(1/LC50(M)) = 0.81 . logD lipw (pH 7) + 1.65 
